FDA Expands Regulatory Use of Non-Animal Testing Methods
Advancements in Organoid and Organ-on-a-Chip Technologies
Korea Pursues International Standardization of Liver Organoids

There is a growing movement in the new drug development process to reduce reliance on animal testing by utilizing testing methods that replicate human physiological characteristics, such as organoids and organ-on-a-chip technologies. Previously discussed mainly from an animal welfare perspective, New Approach Methodologies (NAMs) are expanding their range of applications—as advances in technology and regulatory changes take place—into nonclinical tools for evaluating the toxicity and safety of drug candidates.


According to the pharmaceutical and biotechnology industry on September 23, the U.S. Food and Drug Administration (FDA) announced on September 21 (local time) new rules to replace the terms 'animal test' and 'animal study' in drug and biologics regulations with broader expressions such as 'nonclinical test' and 'nonclinical study.' This clarified that scientifically validated non-animal testing methods—including human cell models, organ-on-a-chip systems, and computer simulations—can also be used for safety assessments.


The increasing attention on NAMs is due to the inherent limitations of traditional animal models. Differences in drug metabolism and immune responses between humans and experimental animals mean that toxicity or safety results confirmed in animals do not always translate directly to humans. Recently, the advancement of organoids—three-dimensional cultures of human cells that partially recapitulate the structure and function of human organs—and microfluidic-based organ-on-a-chip (MPS) technologies has provided enhanced tools to address these issues.


US Revises Animal Testing Regulations... Non-Animal Methods Gain Wider Application View original image

According to a recent report by the Korea Health Industry Development Institute (KHIDI), the period from 2025 to 2026 is expected to mark the transition of NAMs from being policy recommendations to their actual application in regulations. In the United States, the legal foundation to use methods other than animal testing was established through an amendment in 2022. Since then, the country has been formulating more detailed systems of validation and regulatory acceptance. The European Union (EU) also adopted a roadmap in June to gradually reduce the use of animal testing in chemical safety assessments.


Technology itself is evolving as well. Moving beyond replicating single organs, 'multi-organ' technologies are being developed to connect organs such as the liver, kidneys, lungs, and heart, enabling integrated toxicological evaluation as a candidate drug circulates through simulated human body systems. Efforts also continue to integrate induced pluripotent stem cells (iPSCs), artificial intelligence (AI), and automation technologies to enhance the reproducibility and throughput of these tests. According to KHIDI, the global organoid and organ-on-a-chip market is projected to grow from USD 1.42 billion in 2025 to USD 6.87 billion by 2033.


Korea is also accelerating the development and international standardization of these testing methodologies. In April, the OECD added a photo-toxicity non-animal testing method—based on a domestically developed human skin model by the Ministry of Food and Drug Safety—to its official test guidelines. Currently, validation research is underway to have a liver organoid-based toxicity testing method recognized by the OECD. The liver organoid platform, developed for toxicity assessment in this research project, was transferred to Daewoong Pharmaceutical in July and is now being used in industry. Daewoong Pharmaceutical plans to utilize this technology to enhance the precision of preclinical evaluations of new drug candidates.



While Korea is gaining competitiveness in the international standardization and core technology of organoids, it faces limitations due to the absence of specialized validation systems like the FDA's ISTAND and a relative lack of accumulated data. KHIDI noted that there is a need for efforts to verify the reproducibility and reliability of these homegrown technologies so that they can be used for actual regulatory approvals and reviews in Korea. An industry insider said, "If domestic researchers and companies actively participate in international standardization discussions, Korea will not merely follow global standards but will also be able to play a role in setting new ones."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing